Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) announced a quarterly dividend on Friday, January 10th,Wall Street Journal reports. Stockholders of record on Friday, February 21st will be given a dividend of 0.22 per share by the biopharmaceutical company on Monday, March 10th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date is Friday, February 21st. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21.
Royalty Pharma has increased its dividend payment by an average of 7.3% annually over the last three years. Royalty Pharma has a dividend payout ratio of 17.4% meaning its dividend is sufficiently covered by earnings. Research analysts expect Royalty Pharma to earn $4.31 per share next year, which means the company should continue to be able to cover its $0.84 annual dividend with an expected future payout ratio of 19.5%.
Royalty Pharma Trading Up 12.6 %
Shares of RPRX stock traded up $3.29 on Friday, reaching $29.49. 8,018,094 shares of the stock were exchanged, compared to its average volume of 3,134,580. The stock has a 50 day moving average price of $25.90 and a 200 day moving average price of $27.02. The stock has a market cap of $17.38 billion, a PE ratio of 15.28, a P/E/G ratio of 4.36 and a beta of 0.47. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.54 and a quick ratio of 1.54. Royalty Pharma has a one year low of $24.05 and a one year high of $31.66.
Wall Street Analysts Forecast Growth
Royalty Pharma Company Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.
Featured Stories
- Five stocks we like better than Royalty Pharma
- Where Do I Find 52-Week Highs and Lows?
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- What is a Dividend King?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Where to Find Earnings Call Transcripts
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.